logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Brian Timothy McGuinness

This inventor holds 24 USPTO granted patents and 9 published patent applications, primarily in Antibody Therapeutics. Top assignees: Abbott Biotechnology Ltd., Crescendo Biologics Limited, Basf Aktiengesellschaft. Active years: 1998-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian Timothy McGuinness. Retrieved from https://idiyas.com/inventor/brian-timothy-mcguinness

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 

% Patents Active = 58.3

Average Co-Inventor Count = 8.1

ph-index = 15

Forward Citations = 2,305(Granted Patents)


Location History:

  • Hauxton, GB (2000)
  • Comberton, GB (2001 - 2007)
  • Cambridge, GB (1998 - 2024)

Company Filing History:

goldMedal8 out of 17 
 
Abbott Biotechnology Ltd.
 patents
silverMedal8 out of 21 
 
Crescendo Biologics Limited
 patents
bronzeMedal3 out of 10,816 
 
Basf Aktiengesellschaft
 patents
4. 3 out of 259 
 
Medical Research Council
 patents
5. 1 out of 93 
 
Abbvie Biotechnology Ltd
 patents
6. 1 out of 28 
 
Cambridge Antibody Technology Limited
 patents
7. 1 out of 1 
 
Crescendo Biologies Limited
 patent
where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...
Areas of Expertise:
Single Domain Antibodies
Chimeric Antigen Receptor
Therapeutic Molecules
IL-17A Binding Proteins
Prostate Specific Membrane Antigen
Human TNF-alpha
Transgenic Mice
Multivalent Binding Proteins
24 patents (USPTO):Explore Patents
1. 12077595 - Single domain antibodies that bind to CD137 (2024-09-03),
2. 11866510 - Chimeric antigen receptor with single domain antibody (2024-01-09),
3. 11746158 - Therapeutic molecules (2023-09-05),
4. 11667705 - IL-17A binding proteins (2023-06-06),
5. 11591398 - Single domain antibodies to programmed cell death protein 1 (PD-1) (2023-02-28),
6. 11547099 - Transgenic mice (2023-01-10),
7. 11236174 - Therapeutic molecules (2022-02-01),
8. 10975161 - Molecules that bind prostate specific membrane antigen (PSMA) (2021-04-13),
9. 10654924 - IL-17A binding proteins (2020-05-19),
10. 8753633 - Human antibodies that bind human TNFα (2014-06-17),
11. 8414894 - Human antibodies that bind human TNFα and methods of using same (2013-04-09),
12. 8372401 - Human antibodies that bind human TNFα (2013-02-12),
13. 8372400 - Methods of treating disorders using human antibodies that bind human TNFα (2013-02-12),
14. 8206714 - Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa (2012-06-26),
15. 8197813 - Human antibodies that bind human TNFα (2012-06-12),

Title: Innovations by Brian Timothy McGuinness in Biomedicine

Introduction

Brian Timothy McGuinness, a prominent inventor based in Cambridge, GB, is credited with a remarkable portfolio of 24 patents. His innovations primarily focus on biomedicine, particularly in the development of advanced therapeutic compounds.

Latest Patents

Among his latest patents is the creation of *Single domain antibodies that bind to CD137*. This invention encompasses CD137 binding agents and their applications in the treatment, prevention, and detection of diseases. Equally significant is his patent for a *Chimeric antigen receptor with single domain antibody*. This invention relates to chimeric antigen receptors (CARs) featuring one or more single human variable domain antibodies. Notably, it includes CARs that bind to prostate membrane antigen, showcasing his commitment to addressing critical medical challenges.

Career Highlights

Brian has made substantial contributions to the field while working with reputable companies, including Abbott Biotechnology Ltd. and Crescendo Biologics Limited. His expertise and innovative approach have been invaluable in advancing biotechnological research and applications.

Collaborations

Throughout his career, Brian Timothy McGuinness has collaborated with talented professionals such as Jochen G. Salfeld and Deborah J. Allen. These collaborations have resulted in groundbreaking advancements in immunotherapy and genetic engineering.

Conclusion

Brian Timothy McGuinness stands out as a key inventor in the biomedicine field, with his extensive patent portfolio highlighting his innovative spirit. His contributions continue to influence the realms of disease treatment and detection, exemplifying the transformative power of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…